La Jolla Institute For Immunology

La Jolla Institute for Immunology, doing business as La Jolla Institute for Allergy & Immunology, is a premier non-profit research institute headquartered in La Jolla, California, that specializes in advancing understanding of immunological diseases and vaccine development. The institution conducts specialized research services supporting federal agencies' missions in understanding infectious diseases, immunology, allergies, autoimmune disorders, cancer, and vaccine development. With approximately 20 principal investigators supported by substantial NIH funding, the institute serves as a hub for cutting-edge immunological research that bridges basic science discoveries with translational applications relevant to public health threats including emerging infectious diseases, vaccine optimization, and immune-mediated pathologies.

Through federal contracts, La Jolla Institute for Immunology has provided extensive research services to multiple agencies including the National Institute of Allergy and Infectious Diseases (NIAID), the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Department of Veterans Affairs, and the Department of Defense. The institute's contract work has focused on identifying and characterizing T cell epitopes from bacterial pathogens causing pneumonia ($5.5 million definitive contract through September 2029), identifying and validating epitopes conserved across viral pathogen families with pandemic potential ($5.5 million definitive contract through September 2029), and conducting systematic assessment of immunity to Bordetella pertussis using validated assays ($1.05 million definitive contract through September 2025). Additional contract services have included analysis of lymph node fine needle aspirates from baboons vaccinated with pertussis vaccines, processing of biological samples, DNA testing, and research on immunologic cell responses. These contracts have been awarded without set-aside designations and represent work performed as prime contractor and, in some instances, as a subcontractor to entities such as the International AIDS Vaccine Initiative.

Through federal grant awards, La Jolla Institute for Immunology has demonstrated extensive expertise in advancing immunological research across infectious disease, vaccine development, and immunosenescence. The institute has received project grants and cooperative agreements from NIAID totaling tens of millions of dollars for research on HIV vaccine strategies, dengue and Zika virus vaccines, influenza immunity prediction models, herpesvirus immune evasion, germinal center dynamics in vaccine responses, and T cell epitope identification across multiple pathogen families. Additionally, the institute has secured funding from the National Cancer Institute for investigating immune-related adverse events in cancer immunotherapy and phosphorylation site functionality in immunosenescence, grants from the National Institute of General Medical Sciences for studying O-GlcNAc transferase signaling, and funding from the National Center for Advancing Translational Sciences for linking phosphorylation events to transcriptional states. The institute serves as the coordinating center for the Human Immunology Project Consortium (HIPC), managing data standards and providing infrastructure support for multi-center immunological studies. As both a prime grantee and subrecipient on numerous awards from institutions including Scripps Research Institute, Washington University, Georgetown University, Brigham & Women's Hospital, and multiple other academic medical centers, the institute contributes specialized expertise in single-cell transcriptomics, structural biology, epitope discovery, and immune cell characterization to collaborative research initiatives addressing critical gaps in understanding adaptive immunity, vaccine design, and disease pathogenesis.